Clinical trial
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT00020670 · Dana-Farber Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00020670 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia |
| Official title | A Phase I Study of Vaccination With Autologous CD40-Activated Acute Lymphoblastic Leukemia Cells |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | CD 40 |
| Enrollment | 9 |
| Start date | Feb 20, 2001 |
| Primary completion | Apr 1, 2003 |
| Completion | Jul 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 20, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: